Former Leo Pharma candidate heads into big study as FDA fast-tracks assessment

Union Therapeutics is preparing a large-scale phase IIb trial to test its candidate orismilast within atopic dermatitis. On Thursday, the FDA fast-tracked the drug, potentially saving the biotech company "several months" in a potential approval case processing, the company's CFO says.

Morten Boesen, CFO at Union Therapeutics. | Photo: Union Therapeutics

Acquiring drug candidate orismilast from Leo Pharma in summer of last year in a deal valued up to DKK 1.2bn (USD 186.4m) has turned out to be a good decision for Union Therapeutics.

Last month, the company entered into a strategic collaboration and license agreement about orismilast with the Chinese company Innovent Biologics, which could end up paying Union Therapeutics up to USD 267m for the exclusive rights to the research, development and commercialization of the drug in China, Hong Kong, Macau and Taiwan. It was also recently revealed that the US Food and Drug Administration has fast-tracked the former Leo Pharma eczema candidate, which is an oral treatment for atopic dermatitis, commonly known as eczema.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs